SCHEMBL1462829

SCHEMBL1462829

Nc1cc(S(N)(=O)=O)ccc1C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 10/20 0.60
CA12 O43570 7/20 0.60
CA1 P00915 7/20 0.60
CA9 Q16790 7/20 0.60
MAPT P10636 4/20 0.58
KDM4E B2RXH2 3/20 0.58
GAA P10253 3/20 0.58
MEN1 O00255 1/20 0.58
PKM P14618 1/20 0.58
RAB9A P51151 1/20 0.58
KMT2A Q03164 1/20 0.58
CA14 Q9ULX7 6/20 0.52
CA6 P23280 5/20 0.52
CA5A P35218 5/20 0.52
CA7 P43166 5/20 0.52
CA5B Q9Y2D0 5/20 0.52
CYP2C19 P33261 2/20 0.52
CA3 P07451 1/20 0.52
ALDH1A1 P00352 5/20 0.52
HSD17B10 Q99714 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712851 0.86 MAPT (0.57) CA2CA12CA1CA9MAPT
SCHEMBL344115 0.85 KDM4E (0.63) CA2CA12CA1CA9MAPT
SCHEMBL1806929 0.85 CA2 (0.60) CA2CA12CA1CA9MAPT
SCHEMBL1018611 0.85 LMNA (0.61) CA2CA12CA1CA9MAPT
SCHEMBL344111 0.85 ALDH1A1 (0.58) MAPTKDM4EGAAMEN1PKM
SCHEMBL7824801 0.84 CA2 (0.55) CA2CA12CA1CA9MAPT
SCHEMBL27530309 0.82 ALDH1A1 (0.57) CA2CA12CA1CA9MAPT
SCHEMBL24478046 0.81 CA2 (0.55) CA2CA12CA1CA9CA14
SCHEMBL31203331 0.81 CA2 (0.55) CA2CA12CA1CA9CA14
SCHEMBL7538066 0.81 CA2 (0.53) CA2CA12CA1CA9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112442356-A ABX3Preparation method of type stable perovskite quantum dot 南京邮电大学 2021-03-05 CN claimed
US-12467928-B2 N-terminal modifier agents and binders for treating and analyzing peptides DF PEPTIDE ACQUISITION LLC 2025-11-11 US disclosed
US-20240377408-A1 N-TERMINAL MODIFIER AGENTS AND BINDERS FOR TREATING AND ANALYZING PEPTIDES DF PEPTIDE ACQUISITION LLC 2024-11-14 US disclosed
CN-112442356-B ABX 3 Preparation method of type stable perovskite quantum dot 南京邮电大学 2022-10-14 CN disclosed
US-20220283175-A1 METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES Encodia, Inc. (US) 2022-09-08 US disclosed
US-20220283175-A1 METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES Encodia, Inc. (US) 2022-09-08 US disclosed
WO-2022147334-A1 METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES Encodia, Inc. (US) 2022-07-07 WO disclosed
CN-112442356-A ABX3Preparation method of type stable perovskite quantum dot 南京邮电大学 2021-03-05 CN disclosed
US-20140045836-A1 [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-02-13 US disclosed
US-8580783-B2 [1,2,4]triazolo [1,5-c]pyrimidine derivatives as Hsp90 modulators NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-11-12 US disclosed
US-5296487-A Dopamine antagonist for nervous system disorders FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-03-22 US disclosed
US-5264438-A Dopamine receptor agonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-11-23 US disclosed
EP-0436157-A1 Quinazoline derivatives and their preparation FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-07-10 EP disclosed
US-4777247-A Heavy metal-containing monoazo dyes BAYER AKTIENGESELLSCHAFT (DE) 1988-10-11 US disclosed
EP-0240839-A2 Complex metal dyes BAYER AG (DE) 1987-10-14 EP disclosed
US-4067864-A FOR CELLULOSE OR POLYAMIDES CIBA-GEIGY AG (CH) 1978-01-10 US disclosed
US-4039523-A YELLOW CIBA-GEIGY AG (CH) 1977-08-02 US disclosed
US-4017477-A 3-Halogeno-6-hydroxy-pyridone-(2) azo dyestuffs CIBA-GEIGY AG (CH) 1977-04-12 US disclosed
US-3971741-A DISPERSION PIGMENTS BAYER AKTIENGESELLSCHAFT (DT) 1976-07-27 US disclosed
US-3933785-A Azo compounds CIBA-GEIGY AG (CH) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045836-A1 [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS HSP90AB1, HSP90AA1, HSP90AB2P CA2 4383/4885CA12 4883/4885CA1 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.